Benzinga - Feed Your Mind.

Benzinga Professional.

Free Streaming News

ONXX 45.98 -0.75 / Onyx Pharmaceuticals, Inc. FDA

Wednesday, May 23, 2012

New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer Submitted by Bayer (News, ONXX, FDA / Wed, 12:35pm)

Tuesday, May 22, 2012

From Earlier: Phase 3 MISSION trial of Nexavar in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival (News, ONXX, FDA / Tue, 07:09am)

Thursday, April 26, 2012

Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (News, ONXX, FDA / Thu, 08:56am)

Wednesday, February 22, 2012

Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple Myeloma (News, ONXX, FDA / Wed, 05:31pm)

Wednesday, December 14, 2011

Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration (News, ONXX, FDA / Wed, 10:01am)

Monday, December 12, 2011

Onyx Pharmaceuticals Announces FDA Standard Review Designation of Carfilzomib New Drug Application for the Treatment of Relapsed and Refractory Multiple Myeloma (News, ONXX, FDA / Mon, 07:56am)

Tuesday, November 29, 2011

JP Morgan Maintains Overweight Rating on Onyx Pharmaceuticals after FDA Approval (Analyst Color, MM, News, ONXX, Reiteration, FDA, Analyst Ratings / Tue, 11:38am)
Jefferies Maintains Buy on Onyx Pharma After FDA Acceptance of NDA Filing (Analyst Color, News, ONXX, Reiteration, FDA, Analyst Ratings / Tue, 10:56am)
Onyx Pharmaceuticals Announces FDA Acceptance of New Drug Application for Carfilzomib (News, ONXX, FDA / Tue, 09:01am)

Wednesday, October 26, 2011

Onyx Pharmaceuticals Announces Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival (News, ONXX, FDA / Wed, 06:44am)

Wednesday, September 28, 2011

Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma (News, ONXX, FDA / Wed, 08:03am)

Wednesday, August 03, 2011

Onyx Pharmaceuticals and Multiple Myeloma Research Foundation Launch Carfilzomib Expanded Access Program (News, ONXX, FDA / Wed, 04:06pm)

Tuesday, June 07, 2011

Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib at the 16th Congress of the European Hematology Association (News, ONXX, FDA / Tue, 08:06am)

Monday, January 31, 2011

Onyx Pharma Receives FDA Fast-Track Approval For Carfilzomib (ONXX) (ASH, News, ONXX, SPA, FDA / Mon, 05:13pm)
Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib (News, ONXX, FDA / Mon, 05:12pm)

Tuesday, December 07, 2010

Onyx Pharmaceuticals Announces Positive Results From Carfilzomib Phase 2b Study (News, ONXX, FDA / Tue, 08:31am)

From Benzinga's Newsdesk

Realtime News With Pro

Store Professional

Latest from Premium

Brain Trust

Embedded Examiners Always Married...

William K. Black

More from William K. Black:

Options in Portfolio Allocation:...

Michael Thomsett

More from Michael Thomsett:

Orbitz Worldwide: Its Symbol Says...

Ted Allrich

More from Ted Allrich:

Are Taxes Too Low in the USA?

Barbara Friedberg

More from Barbara Friedberg:

The Real Deal on Wall Street: 5...

Brian Sozzi

More from Brian Sozzi:

The Facebook IPO: What's Not to...

Michael Prus

More from Michael Prus:

DOW Reversal Predicted by the...

Stephen Bigalow

More from Stephen Bigalow:

Will The Real Housing Market Up?...

Logan Mohtashami

More from Logan Mohtashami:

Financial Careers and Career - of...

George Mentz

More from George Mentz:

Adapting for Traders

Adrienne Toghraie

More from Adrienne Toghraie:

iPad Future Growth

Daniel Ho

More from Daniel Ho:

Insider Sentiment is Neutral to...

Nejat Seyhun

More from Nejat Seyhun:

7 Deadly Sins of Investing: Don't...

Jay Peroni

More from Jay Peroni: